Eminent Domain for Overpriced Drugs

Today on TAP: Exhibit A is the case of the EpiPen. It should cost a few dollars rather than the $600 or more charged by monopolist Viatris.

by

The American Prospect is nonprofit, reader-funded journalism—and we need your help.

Our reporters dig deep, hold power to account, and explain how policy shapes people’s lives. If you value independent journalism that goes beyond the headlines, now’s the time to support it.

Here’s how you can help:
Donate to power fearless reporting
Subscribe to get our print magazine 6x/year. 

Every dollar funds our in-depth reporting. 


Donate Now. Subscribe here.